APASL_2026_Istanbul

Hepatology International · Published 2026-08-04 · DOI 10.1007/s12072-026-11095-3

Authors being retrieved — see the publisher record. https://doi.org/10.1007/s12072-026-11095-3

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• Clinical trial endpoints for metabolic dysfunction and alcohol associated steatotic liver disease · Hepatology International · 2026 · Same journal
• APASL clinical practice guidelines on the management of chronic hepatitis B infection: a 2026 update · Hepatology International · 2026 · Same journal
• APASL STC on Wilson Disease; New Delhi 2026 · Hepatology International · 2026 · Same journal
• Tolvaptan for hyponatremia in patients with cirrhosis: a post hoc subgroup analysis of a multicenter, randomized, double-blind, placebo-controlled trial · Hepatology International · 2026 · Same journal
• Phosphatidylethanol versus clinical criteria to diagnose alcohol use relapse after liver transplantation: a prospective cohort study · Hepatology International · 2026 · Same journal
• Precision medicine for G-CSF in ACLF: the biomarker gap · Hepatology International · 2026 · Same journal
• Response to letter to editor—Machine learning prediction of rapid HBsAg seroclearance at week 24 in inactive carriers treated with pegylated interferon · Hepatology International · 2026 · Same journal
• Methodological Considerations in the MAFLD-MASLD Dichotomy for Cardiac Risk Assessment · Hepatology International · 2026 · Same journal
• Obstructive sleep apnea mediates the association between body mass index and metabolic dysfunction-associated steatotic liver disease in patients with obesity · Hepatology International · 2026 · Same journal
• Gout is independently associated with occult hepatic fibro-inflammation independent of obesity: a multi-cohort study using MRI-cT1 and elastography · Hepatology International · 2026 · Same journal